Berlin, Germany & Seoul, South Korea, 3 December 2025 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed a supply agreement with SK Biopharmaceuticals, a biotech company specializing in research, development, and commercialization of treatments of central nervous system (CNS) disorder, active in the field of radiopharma and based in South Korea. Eckert & Ziegler will supply SK Biopharmaceuticals with Actinium-225 (Ac-225) to accelerate their research and development activities in radiopharmaceutical therapies.

SK Biopharmaceuticals’ development pipeline includes SKL35501, an innovative radiopharmaceutical labeled with Ac-225 with potential in the treatment of multiple types of cancer, including colorectal, breast, pancreatic, and head and neck cancers. By securing reliable supply of the alpha emitting radioisotope from Eckert & Ziegler, the company will be able to drive forward this as well as further programs from their expanding pipeline.

“We are happy to support SK Biopharmaceuticals with our supply of GMP compliant Ac-225 in their promising preclinical and clinical programs,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “Ac-225 remains one of the most in-demand radioisotopes for the development of next-generation radiopharmaceuticals, and we are pleased to contribute to the advancement of these cancer therapies.”

“Securing a stable supply of Ac-225, the key source material for radiopharmaceutical therapy, is a prerequisite for success. We are pleased to have concluded this agreement with Eckert & Ziegler, a reliable provider with long time track record for high-quality radioisotopes to be used in pharma,” said Donghoon Lee, CEO of SK Biopharmaceuticals. “Building on our proactive global partnership and diversified supply chain, we will take a major step forward in advancing into the global oncology treatment market.”

Eckert & Ziegler reliably supplies Gallium-68, Lutetium-177, Yttrium-90, and Actinium-225 in GMP quality to leading pharmaceutical companies and research institutions worldwide. With expertise in radioisotope production as well as global logistics and CDMO services, the company is committed to continuously supporting the development and delivery of innovative radiopharmaceuticals.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About SK Biopharmaceuticals 
SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea’s second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals, and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME’s 100 Most Influential Companies of 2023. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about SK Inc., visit https://sk-inc.com/en/main/mainpage.aspx. For more information about SK Biopharmaceuticals, visit www.skbp.com/eng

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

SK Biopharmaceuticals Public Relations Team
skbp.pr@sk.com

Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate ⁶⁸Ga-PentixaFor in Hypertension

• FDA scientific advice meeting provides guidance on planned Phase 3 study of radiodiagnostic lead candidate in treatment-resistant hypertension / primary aldosteronism
• Further details on Phase 3 clinical setup expected upon receipt of the FDA’s official meeting minutes

Berlin, Germany, December 03, 2025 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing first-in-class radiopharmaceuticals, has received encouraging feedback from a TypeB pre‑IND meeting with the U.S. Food and Drug Administration (FDA). The discussion addressed key elements of Pentixapharm’s planned Phase 3 PANDA study with [⁶⁸Ga]Ga-PentixaFor, a CXCR4-directed radiodiagnostic intended to significantly improve the diagnostic pathway for patients with treatment-resistant hypertension and primary aldosteronism. Despite its substantial clinical and societal impact, primary aldosteronism remains widely underdiagnosed, and earlier, more accurate detection represents a significant unmet medical need.

During the meeting, the FDA provided initial, non-binding feedback on key components of Pentixapharm’s draft Phase 3 clinical protocol, including proposed inclusion criteria and design as well as statistical parameters. The FDA’s input is considered essential for the Phase 3 study to meet effectiveness and shaping the final Investigational New Drug (IND) submission.

“We appreciate the constructive dialogue with the FDA and the opportunity to align on technical details and clarify outstanding questions,” said Dr. Dirk Pleimes, CEO and CMO of Pentixapharm. “The preliminary feedback supports our plan to advance [⁶⁸Ga]Ga-PentixaFor into Phase 3 and provides an important step toward bringing a potentially scalable and non-invasive diagnostic tool to patients with primary aldosteronism who currently lack reliable, non-invasive options. Once we have received and reviewed the formal FDA meeting minutes, we will refine our Phase 3 study design accordingly and continue to update the market as we progress along our IND strategy.”

About ⁶⁸Ga-PentixaFor in treatment-resistant hypertension and primary aldosteronism

[⁶⁸Ga]Ga-PentixaFor is a novel gallium-68-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Clinical experience with [⁶⁸Ga]Ga-PentixaFor PET/CT in approximately 1,600 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo.

Recent research has shown strong CXCR4 overexpression in aldosterone-producing adrenal tumors, a hallmark of unilateral primary aldosteronism. Primary aldosteronism is a common but historically underdiagnosed cause of secondary hypertension, largely because reliably distinguishing unilateral from bilateral disease remains challenging with current diagnostic tools. Unilateral disease is typically treated by surgical removal of the affected adrenal gland whereas bilateral disease requires life-long medical therapy. By visualizing CXCR4 expression in aldosterone-producing tissue, [⁶⁸Ga]Ga-PentixaFor has the potential to support more reliable subtyping of primary aldosteronism and thereby better guide appropriate treatment decisions.

About Pentixapharm

Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops precision diagnostics and therapeutics in oncology and cardiology to transform patient care. Its clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including a Phase 3-ready candidate for the improved diagnosis of hypertensive patients with primary aldosteronism, which is intended to enable targeted treatment of the underlying causes of hypertension. CXCR4-based developments also include pioneering therapeutic programs in hematological cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, Pentixapharm is poised to deliver meaningful patient benefit and sustainable growth in one of the fastest-growing areas of precision medicine.

Pentixapharm Investor and Media Contact

ir@pentixapharm.com

DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio 

DNA-based Colorectal Cancer Screening as a Home Test 

BERKELEY, US, MAINZ and BERLIN, Germany – December 02, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer,today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another important milestone in Mainz Biomed’s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed’s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany.

Colorectal cancer is one of the most common yet preventable cancers worldwide. In Germany alone, around 60,000 new cases are diagnosed each year — a clear indicator of the need for highly effective early detection measures. By integrating Mainz Biomed’s advanced DNA diagnostics into DoctorBox’s digital healthcare platform, this collaboration establishes a highly innovative model of care that can significantly expand access to ColoAlert.

“With DoctorBox, we are gaining a strong partner that enables us to offer ColoAlert exactly where prevention can take place today — at home,” said Guido Baechler, CEO of Mainz Biomed. “Together, we are lowering barriers to colorectal cancer screening and providing easy access to DNA-based early detection.”

“ColoAlert fits perfectly into our portfolio of next-generation DNA- and RNA-based tests. Thus, innovative colorectal cancer screening becomes another cornerstone of our digital preventive healthcare platform,” said Julian Maar, CEO of DoctorBox.

The DoctorBox app brings together modern preventive healthcare services on a single platform: with over one million registered users and more than ten million test results transmitted, DoctorBox ranks among Europe’s leading digital prevention solutions. The offering includes guideline-based preventive-care reminders – personalized by age, sex, and risk profile. Additional services include at-home tests and locally accessible diagnostics, for example for early detection of colorectal, cervical, and prostate cancer (self-pay or reimbursed). Measures for sexual health, allergies, as well as innovative analyses, digital evaluation and support – including the delivery of findings, recommendations for action, and video consultations directly within the app – are also part of the DoctorBox offering.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About DoctorBox

DoctorBox is setting the new standard for prevention in Europe — made in Germany.

As one of Germany’s leading digital solutions for smart preventive healthcare, DoctorBox empowers more than one million users in Germany and other European countries to manage their health prevention easily, digitally, and independently. Whether through reminders, at-home tests, or local diagnostics, DoctorBox makes preventive healthcare accessible and part of everyday life.

To learn more, visit doctorbox.de.

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples.

To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact ir@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices

Rellingen, November 28, 2025 – Viromed Medical AG, a specialist in medical technologies, and HELLMUT RUCK GmbH, a leading provider of podiatry, foot care, and cosmetic solutions, announce the conclusion of an exclusive partnership for Europe, including Switzerland. As part of this cooperation, RUCK will exclusively distribute innovative plasma devices as an OEM product. The collaboration combines the technological expertise of Viromed with the strong market position and sales experience of RUCK. The aim is to provide professional users in podiatry, foot care, cosmetics, and medicine with a forward-looking solution for hygienic and skin-friendly treatments.

Notifying person:
Uwe Perbandt, CEO Viromed Medical AG

Contact Viromed:
E-Mail: kontakt@viromed-medical.de

Asklepios Group: Solid third quarter of 2025 –  successful placement of Social Schuldschein loan strengthens financing basis
 

• Patient numbers up 6.3% to reach 2.9 million
• Consolidated revenues of EUR 4,770.1 million
• Successful placement of new Social Schuldschein loan for EUR 600.0 million

In the first nine months of 2025, the Asklepios Group put in an overall solid operating performance. Despite healthcare policy challenges and a difficult economic environment, the number of patients was once again increased and consolidated profit was improved. Parallel to that, the Group has also given a significant boost to its sustainable financing.

From January to September 2025, the Group’s healthcare facilities treated a total of 2,915,971 patients (9M 2024: 2,742,439) – an increase of roughly 6.3% over the previous year. While moderate growth in patient numbers was observed in the inpatient area, the overall trend was mainly driven by growth in the outpatient area.

Consolidated revenue totalled EUR 4,770.1 million (9M 2024: EUR 4,350.8 million) in the first nine months, which is an increase of 9.6%. Consolidated net income after tax (EAT) for the period increased to EUR 114.5 million (9M 2024: EUR 88.2 million). Total investments over the reporting period were EUR 302.8 million (9M 2024: EUR 232.4 million).

On 29 October 2025, the Asklepios Group successfully placed a Social Schuldschein loan in the amount of EUR 600.0million. It was issued under the Social Finance Framework for early refinancing of maturities for the years 2025 to 2027 and was subscribed by both existing and international investors. With maturities of 3, 5, 7 and 10 years as well as a 52% share of international investors, the capital base was further diversified.

Hafid Rifi, CFO of the Asklepios Group, noted:

“The new Social Schuldschein loan allows us to further develop the strategy of our finance portfolio and to actively manage our maturities. What is especially encouraging is the strong interest shown by international investors, clearly underscoring the trust in our sustainable course.“

About Asklepios

Asklepios Kliniken is one of the leading operators of private hospitals and healthcare facilities in Germany. The hospital group has an established track record for delivering high-quality medical care to its patients with a clear commitment to medical quality, innovation and social responsibility. Currently, the Asklepios Group has some 160 healthcare facilities throughout Germany. These include acute hospitals of all care levels, university hospitals, specialised clinics, psychiatric and forensic facilities, rehabilitation hospitals, nursing homes and medical care centres. During financial year 2024, over 3.6 million patients were treated at Asklepios’ healthcare facilities. The Group employs more than 70,000 persons.

The Quarterly Statement can be accessed as of today at Asklepios – Publikationen.

Investor Relations contact:

Sarah Ludwig

Head of Investor Relations

Asklepios Kliniken GmbH & Co. KGaA

Debusweg 3 – 61462 Königstein-Falkenstein

Tel.: +49 6174 9011-72

E-mail: ir@asklepios.com

Media contact:

Rune Hoffmann

Head of Corporate Communications & Marketing

Asklepios Kliniken GmbH & Co. KGaA

Rübenkamp 226 – 22307 Hamburg

Tel.: +49 40 1818-82 6630

Fax: +49 40 1818-82 6639

E-mail: presse@asklepios.com

Visit Asklepios on the Internet, Facebook or YouTube:

www.asklepios.com

www.gesundleben.asklepios.com
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken

Sign up for the Asklepios Newsletter:

https://www.asklepios.com/konzern/newsletter-anmeldung/

Nursing blog: https://wir-sind-pflege.blog/

AD HOC ANNOUNCEMENT

Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care

Pinneberg, November 26, 2025 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), confirms market rumors that the company is in advanced talks with a global MedTech company in the field of wound treatment about signing a cooperation agreement. This mainly involves the use of the cold plasma medical device ViroCAP®/OEM to support wound healing.

Viromed will inform shareholders of further developments in an appropriate manner and in accordance with the legal obligations.

Notifying person:
Uwe Perbandt, CEO Viromed Medical AG

Contact Viromed:
E-Mail: kontakt@viromed-medical.de

Immunic to Participate in the 8th Annual
Evercore ISI Healthcare Conference in December
 

NEW YORK, November 26, 2025 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL.

A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.

Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu at: jessica.breu@imux.com. 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com